BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17687341)

  • 1. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study.
    Verset G; Verslype C; Reynaert H; Borbath I; Langlet P; Vandebroek A; Peeters M; Houbiers G; Francque S; Arvanitakis M; Van Laethem JL
    Br J Cancer; 2007 Sep; 97(5):582-8. PubMed ID: 17687341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.
    Barbare JC; Bouché O; Bonnetain F; Dahan L; Lombard-Bohas C; Faroux R; Raoul JL; Cattan S; Lemoine A; Blanc JF; Bronowicki JP; Zarski JP; Cazorla S; Gargot D; Thevenot T; Diaz E; Bastie A; Aparicio T; Bedenne L
    Eur J Cancer; 2009 Jul; 45(10):1788-97. PubMed ID: 19303768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study.
    Prete SD; Montella L; Caraglia M; Maiorino L; Cennamo G; Montesarchio V; Piai G; Febbraro A; Tarantino L; Capasso E; Palmieri G; Guarrasi R; Bianco M; Mamone R; Savastano C; Pisano A; Vincenzi B; Sabia A; D'Agostino A; Faiola V; Addeo R
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):837-44. PubMed ID: 20041325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial.
    Pan DY; Qiao JG; Chen JW; Huo YC; Zhou YK; Shi HA
    Hepatobiliary Pancreat Dis Int; 2003 May; 2(2):211-5. PubMed ID: 14599971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.
    Yuen MF; Poon RT; Lai CL; Fan ST; Lo CM; Wong KW; Wong WM; Wong BC
    Hepatology; 2002 Sep; 36(3):687-91. PubMed ID: 12198662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.
    Becker G; Allgaier HP; Olschewski M; Zähringer A; Blum HE;
    Hepatology; 2007 Jan; 45(1):9-15. PubMed ID: 17187405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide.
    Cebon J; Findlay M; Hargreaves C; Stockler M; Thompson P; Boyer M; Roberts S; Poon A; Scott AM; Kalff V; Garas G; Dowling A; Crawford D; Ring J; Basser R; Strickland A; Macdonald G; Green M; Nowak A; Dickman B; Dhillon H; Gebski V;
    Br J Cancer; 2006 Oct; 95(7):853-61. PubMed ID: 16953241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Octreotide alone or in combination with rofecoxib as palliative treatment for advanced hepatocellular cancer.
    Treiber G; Röcken C; Wex T; Malfertheiner P
    Z Gastroenterol; 2007 May; 45(5):369-77. PubMed ID: 17503315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide.
    Rabe C; Pilz T; Allgaier HP; Halm U; Strasser C; Wettstein M; Sauerbruch T; Caselmann WH
    Z Gastroenterol; 2002 Jun; 40(6):395-400. PubMed ID: 12055662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial.
    Chow PK; Tai BC; Tan CK; Machin D; Win KM; Johnson PJ; Soo KC;
    Hepatology; 2002 Nov; 36(5):1221-6. PubMed ID: 12395333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen].
    Wenger FA; Zieren HU; Jacobi CA; Müller JM
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1348-50. PubMed ID: 9931878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma and octreotide: treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage.
    Plentz RR; Tillmann HL; Kubicka S; Bleck JS; Gebel M; Manns MP; Rudolph KL
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1422-8. PubMed ID: 16105131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
    Pritchard KI; Shepherd LE; Chapman JA; Norris BD; Cantin J; Goss PE; Dent SF; Walde D; Vandenberg TA; Findlay B; O'Reilly SE; Wilson CF; Han L; Piura E; Whelan TJ; Pollak MN
    J Clin Oncol; 2011 Oct; 29(29):3869-76. PubMed ID: 21911723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases.
    Yang TS; Chang HK; Chen JS; Lin YC; Liau CT; Chang WC
    J Gastroenterol; 2004; 39(4):362-9. PubMed ID: 15168248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with Child-Pugh B cirrhosis.
    Dhooge M; Coriat R; Mir O; Perkins G; Brezault C; Boudou-Rouquette P; Goldwasser F; Chaussade S
    Oncology; 2013; 84(1):32-8. PubMed ID: 23076239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma.
    Gallo C; De Maio E; Di Maio M; Signoriello G; Daniele B; Pignata S; Annunziata A; Perrone F;
    BMC Cancer; 2006 Jul; 6():196. PubMed ID: 16863588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402).
    Doffoël M; Bonnetain F; Bouché O; Vetter D; Abergel A; Fratté S; Grangé JD; Stremsdoerfer N; Blanchi A; Bronowicki JP; Caroli-Bosc FX; Causse X; Masskouri F; Rougier P; Bedenne L;
    Eur J Cancer; 2008 Mar; 44(4):528-38. PubMed ID: 18242076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
    Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL
    Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with all-trans retinoic acid plus tamoxifen and vitamin E in advanced hepatocellular carcinoma.
    Clerici C; Castellani D; Russo G; Fiorucci S; Sabatino G; Giuliano V; Gentili G; Morelli O; Raffo P; Baldoni M; Morelli A; Toma S
    Anticancer Res; 2004; 24(2C):1255-60. PubMed ID: 15154656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma.
    Attia S; Holen KD; Thomas JP; Richie K; Dzelak T; Teeter K; Warren D; Bilger A; Fine J; Eickhoff J; Drinkwater N; Mulkerin D; Morgan-Meadows S
    Clin Adv Hematol Oncol; 2008 Jan; 6(1):44-54. PubMed ID: 18322441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.